Drug Repurposing Series
Drug repurposing explores new therapeutic applications for existing drugs and clinical-stage compounds. Leveraging available pharmacological and clinical data may help reduce early-stage development time and costs while informing further evaluation of safety and efficacy.
Drug Repurposing Series contains compounds that have either entered clinical trial phase or have been approved. Detailed indications, clinical information and approval authorities can be provided to facilitate subsequent research.
Drug Repurposing Series contains compounds that have either entered clinical trial phase or have been approved. Detailed indications, clinical information and approval authorities can be provided to facilitate subsequent research.
-
Withdrawn Drug Compound Library232 compoundsHY-L140
-
EMA-Approved Drug Library730 compoundsHY-L116
-
Pediatric Drug Library714 compoundsHY-L104
-
Drug Repurposing Compound Library5,161 compoundsHY-L035
-
Drug Repurposing Compound Library Plus6,158 compoundsHY-L035P
-
Clinical Compound Library2,579 compoundsHY-L026
-
Clinical Compound Library Plus3,310 compoundsHY-L026P
-
NMPA-Approved Drug Library1,534 compoundsHY-L053
-
FDA-Approved Drug Library Mini3,239 compoundsHY-L022M
-
FDA-Approved Drug Library3,239 compoundsHY-L022
-
FDA-Approved Drug Library Plus3,666 compoundsHY-L022P
-
FDA Approved & Pharmacopeial Drug Library3,751 compoundsHY-L066
-
Off-patent Drug Library2,924 compoundsHY-L141
-
FDA-Approved Anticancer Drug Library1,545 compoundsHY-L122
-
Classic FDA-Approved Drug Library168 compoundsHY-L261